Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Primary Care Screening Flops in Detecting Diabetic Eye Disease
(MedPage Today) -- Fundoscopic examination in a primary care setting was no boon for the detection of diabetic retinopathy, a retrospective cohort study showed.
Among 59 patients with diabetes who underwent both a primary care exam and a professional... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 28, 2022 Category: Cardiology Source Type: news
Janssen Presents Initial Results from the Phase 2 RAGNAR Study of BALVERSA ® (erdafitinib) in Patients with Advanced Solid Tumors with FGFR Alterations
CHICAGO, ILLINOIS, June 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced initial results from the pivotal Phase 2 RAGNAR study evaluating the investigational use of BALVERSA® (erdafitinib), a fibroblast growth factor receptor (FGFR) kinase inhibitor, in patients with advanced solid tumors with prespecified FGFR alterations. At a planned interim analysis (IA), responses were observed across a variety of FGFR-driven solid tumors for patients who had exhausted standard treatment options prior to being treated with BALVERSA®.[1] These results will be featured in an oral presentation (...
Source: Johnson and Johnson - June 7, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news
Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA ® (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor
September 17, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1b/2 NORSE (NCT03473743) study evaluating BALVERSA® (erdafitinib) in combination with cetrelimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, compared to BALVERSA® monotherapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations who are ineligible for cisplatin, a current standard of care treatment for mUC. The results were highlighted in an oral presentation at t...
Source: Johnson and Johnson - September 17, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A comp...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said Craig Tendler, M...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Catching the red eye: A retrospective review of factors associated with retinal hemorrhage in child physical abuse - Moody S, Casar AM, Jenkins T, Farooqui Z, Shebesta K, Kotagal M, Falcone RA.
BACKGROUND/PURPOSE: Accurate identification of child physical abuse is crucial during the evaluation of injured children. Retinal hemorrhages (RH) are used for diagnosis, but clear criteria for screening with direct fundoscopic exam are lacking. We sought ... (Source: SafetyLit)
Source: SafetyLit - September 8, 2020 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news
Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet needs continue...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Make the Diagnosis: 10 Year Hiatus
(MedPage Today) -- Case Findings: A 54 year old female presents to your office for an eye check-up. She has not seen an optometrist in over 10 years, and never required glasses or had any problems with her eyes. She has no specific concerns.
The patient tells you she is otherwise healthy, although again she has not seen a medical doctor in over 10 years. She is on no medications and has no allergies to medications. Family history is unremarkable.
On exam best-corrected visual acuity is 20/40 bilaterally. Pressures are normal at 12 and 13 in the right and left eyes, respectively. Anterior segment exam is normal in both ey...
Source: MedPage Today Ophthalmology - May 17, 2017 Category: Opthalmology Source Type: news
Dx: Ruptured Vessel
The ultrasound image shows a view of the globe with the retina at the bottom of the image. The vitreous humor appears anechoic (black) and the retina echoic (gray). Just in front of the retina is a small echoic area that was not present in the unaffected eye. It does not appear to be connected to the retina, making it a bit atypical in appearance for a retinal detachment. A vitreous detachment could also look like this on ultrasound, but would also be attached at some point to the posterior globe. Examination by ophthalmology with his fancy gadgets and unique skill set revealed that this echoic area seen on ultrasound was ...
Source: EPMonthly.com - December 2, 2016 Category: Emergency Medicine Authors: Logan Plaster Tags: Uncategorized Source Type: news
Make the Diagnosis: Ocular Oddity
(MedPage Today) -- Case Findings: A 45-year-old male presents with blurred vision in the left eye. He has no prior history of eye disease. The results of a fundoscopy showed lines of crystalline deposits following the path of the retinal arterioles.
What is your diagnosis? (Source: MedPage Today Ophthalmology)
Source: MedPage Today Ophthalmology - October 16, 2015 Category: Opthalmology Source Type: news
Long-term visual damage after acute methanol poisonings: longitudinal cross-sectional study in 50 patients - Zakharov S, Pelclova D, Diblik P, Urban P, Kuthan P, Nurieva O, Kotikova K, Navratil T, Komarc M, Belacek J, Seidl Z, Vaneckova M, Hubacek JA, Bezdicek O, Klempir J, Yurchenko M, Růžička E, Miovský M, Janíková B, Hovda KE.
CONTEXT: Visual disturbances due to the toxic effect of formic acid in acute methanol poisonings are generally transient. The subjective symptoms of visual toxicity may resolve within few weeks and fundoscopic signs of acute optic neuropathy subside within... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - September 19, 2015 Category: Global & Universal Tags: Alcohol and Other Drugs Source Type: news
